Xeomin is free from complexing proteins.
In contrast to the other botulinum toxin products Xeomin only contains the 150kD neurotoxin without complexing proteins which have no therapeutic function and don't influence the diffusion of the neurotoxin. In large clinical Phase III studies (blepharospasm and cervical dystonia) Xeomin showed the same efficacy and profile of adverse events as Botox. Whereas competing product must be stored refrigerated, Xeomin is stable for 3years at room temperature.
Frevert
Jürgen
J
Merz Pharmaceuticals GmbH, Hermannswerder Haus 15, 14473 Potsdam, Germany. juergen.frevert@merz.de
D001905:Botulinum Toxins / Q000737:chemistry*; D019274:Botulinum Toxins, Type A / Q000737:chemistry*; D004340:Drug Contamination; D009465:Neuromuscular Agents / Q000737:chemistry*
D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA